@article{1171b1ab26bf4861892ad319f8e87420,
title = "My treatment approach to rheumatoid arthritis",
abstract = "The past decade has brought important advances in the understanding of rheumatoid arthritis and its management and treatment. New classification criteria for rheumatoid arthritis, better definitions of treatment outcome and remission, and the introduction of biologic response-modifying drugs designed to inhibit the inflammatory process have greatly altered the approach to managing this disease. More aggressive management of rheumatoid arthritis early after diagnosis and throughout the course of the disease has resulted in improvement in patient functioning and quality of life, reduction in comorbid conditions, and enhanced survival.",
author = "Davis, {John M.} and Matteson, {Eric L.}",
note = "Funding Information: Potential Competing Interests: Dr Davis is an investigator on studies with Centocor Inc, Malvern, PA; VA Cooperative Studies Program, US Department of Veterans Affairs, Washington, DC; Genentech, Inc, South San Francisco, CA; Novartis Corp, East Hanover, NJ; Rheumatoid Arthritis Investigational Network/University of Nebraska Medical Center, Omaha; and UCB Pharma, Inc, Smyrna, GA. He has received grant support or contracts from the Arthritis Foundation , Indianapolis, IN; Centocor ; Genentech ; Mayo Foundation , Rochester, MN; Myriad RBM, Inc , Austin, TX; National Center for Research Resources and National Institutes of Arthritis and Musculoskeletal and Skin Diseases , National Institutes of Health , Bethesda, MD; Novartis Corp ; UCB Pharma, Inc ; and University of Nebraska Medical Center Cooperative Studies Program . ",
year = "2012",
month = jul,
doi = "10.1016/j.mayocp.2012.03.011",
language = "English (US)",
volume = "87",
pages = "659--673",
journal = "Mayo Clinic proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "7",
}